Compare · CAH vs MDT
CAH vs MDT
Side-by-side comparison of Cardinal Health Inc. (CAH) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CAH focuses on Other Pharmaceuticals, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $109.98B, about 2.0x CAH ($55.66B).
- Over the past year, CAH is up 56.1% and MDT is down 5.4% - CAH leads by 61.4 points.
- MDT has been more active in the news (14 items in the past 4 weeks vs 11 for CAH).
- Both have 25 recent analyst ratings on file.
- Company
- Cardinal Health Inc.
- Medtronic plc.
- Price
- $239.40+0.75%
- $86.38+0.56%
- Market cap
- $55.66B
- $109.98B
- 1M return
- +2.44%
- +4.88%
- 1Y return
- +56.05%
- -5.36%
- Industry
- Other Pharmaceuticals
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 11
- 14
- Recent ratings
- 25
- 25
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CAH
- Chief Executive Officer Hollar Jason M. was granted 187,965 shares, increasing direct ownership by 94% to 387,965 units (SEC Form 4)
- Chief Information Officer Greene Michelle D. was granted 17,230 shares, increasing direct ownership by 141% to 29,460 units (SEC Form 4)
- Chief Financial Officer Alt Aaron E was granted 58,738 shares, increasing direct ownership by 222% to 85,146 units (SEC Form 4)
- CEO, PSS Segment Weitzman Deborah was granted 54,823 shares, increasing direct ownership by 104% to 107,700 units (SEC Form 4)
- CEO, GMPD Segment Mason Stephen M was granted 46,992 shares, increasing direct ownership by 184% to 72,482 units (SEC Form 4)
- Chief Legal/Compliance Officer Mayer Jessica L was granted 46,992 shares, increasing direct ownership by 136% to 81,419 units (SEC Form 4)
- Chief Accounting Officer Scherer Mary C. was granted 2,610 shares, increasing direct ownership by 75% to 6,105 units (SEC Form 4)
- Chief Human Resources Officer Pitteroff Valerie Christine was granted 2,610 shares, increasing direct ownership by 33% to 10,632 units (SEC Form 4)
- Cardinal Health Inc. filed SEC Form 8-K: Leadership Update
- Cardinal Health expands home care business with two tuck-in acquisitions
Latest MDT
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)
- EVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)
- EVP & Chief Financial Officer Pieton Thierry was granted 11,537 units of Ordinary Shares, increasing direct ownership by 30% to 49,645 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael was granted 57,107 units of Ordinary Shares and covered exercise/tax liability with 3,356 units of Ordinary Shares, increasing direct ownership by 84% to 117,420 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 3,074 units of Ordinary Shares and was granted 9,230 units of Ordinary Shares, increasing direct ownership by 16% to 43,669 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey was granted 41,533 units of Ordinary Shares and covered exercise/tax liability with 15,810 units of Ordinary Shares, increasing direct ownership by 9% to 327,866 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle covered exercise/tax liability with 2,069 units of Ordinary Shares, decreasing direct ownership by 9% to 20,375 units (SEC Form 4)